Responses
Infectious diseases
Protocol
A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial)
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 23 November 2015
- Published on: 23 November 2015Trial protocol must explain how possible adverse effects will be looked for and managedShow More
Grigg and colleagues have published their design for the first-ever randomised controlled in Plasmodium knowlesi malaria, to be carried out over a 2-year period in Sabah [1]. We are concerned because one arm of the trial involves a fixed combination of mefloquine + artesunate.
The authors of the study protocol rightly acknowledge that mefloquine is associated with neuropsychiatric adverse events (AEs), but go on...
Conflict of Interest:
None declared.